Biocept updates on its coronavirus testing volume and initiatives for the remainder of the year

Biocept, Inc. (NASDAQ:BIOC) CEO Mike Nall tells Proactive it has received more than 250,000 samples received to date for coronavirus processing through its RT-PCR technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory. Nall says he expects COVID-19 RT-PCR testing will be a significant component of the business until the pandemic subsides, however, he says the group is “well positioned” to grow its liquid biopsy oncology business in 2021.